ORTHOMETRIX, INC.

March 12, 2015

Dear Shareholder:

I am pleased to report that our Company has posted another profitable year. This was mainly due to continuing improvement in research funding in Canada, which benefited our peripheral Quantitative Computed Tomography (pQCT™) systems sales, while NIH funding remained depressed in the US. Consequently, our pQCT™ sales increased by 48% in 2014 as compared to 2013. The continuing weakness of the general economy, which particularly affected the sales of our VibraFlex® Whole Body Vibration (WBV) systems in 2012, seems to continue to ease up and sales of WBV systems increased by 35% in 2014 as compared to 2013. Enclosed is a copy of our 2014 audited financial statements for your review.

You will note that our total sales increased by 43% from $1,072,145 to $1,529,765. We were able to maintain Gross Margin around 70%, mainly as a result of the fluctuation in product mix and currency exchange rates (our purchases are primarily made in Euros and our sales in US dollars). We posted a net profit of $416,149 or $0.0078 /share compared to a net profit of $58,009 or $0.0011/share in 2014, a 617% improvement.

Without underestimating the value of these improvements, I must reiterate that the future of our company will continue to depend upon having healthcare mass-market devices reimbursed in the US, without which we remain 100% dependent on the North American pQCT research market, which is limited and unpredictable. Therefore, I set out seven years ago to acquire new medical devices with substantial market potential to distribute worldwide. It took longer than expected but I think that we may be on the verge of being rewarded for our efforts.

In 2013, as reported in my last Shareholders Letter, we acquired from Andante Medical Devices, Inc. the exclusive rights to distribute the SmartStep® worldwide, except in Israel. The SmartStep is a patented gain training device with biofeedback that helps patient re-learn how to walk correctly after an orthopedic trauma (lower-limb sports injuries, hip/knee replacement, amputation) or a neurological trauma (stroke, Parkinson's). There are over 1 million hip/knee surgery procedures per year in the US market alone.

In 2014, we acquired from Encore Path, Inc., the exclusive rights to distribute worldwide the Tailwind®, a patented Bilateral Arm Trainer with Rhythmic Auditory Cueing (BATRAC) that was developed at the University of Maryland School of Medicine's Department of Physical Therapy and Rehabilitation Services. The Tailwind has been shown to improve arm movement in stroke patients with paralysis. Like the SmartStep, US sales of Tailwind plummeted in 2012 due to the lack of specific reimbursement. There are over 500,000 new surviving stroke patients per year in the US market alone, and an existing population of 5 million of survivors.


I am pleased to report that, under our guidance, both manufacturers filed an application with the Center for Medicare and Medicaid Services (CMS) in 2014 to obtain an HCPCS reimbursement code. Both of these applications were approved and appeared in the Federal Register in February 2015. Final notification of code approval to the manufacturer is scheduled for November 2015. If approved, the codes will be in effect in 2016.

Reimbursement approval for either device will allow our Company to resume growth since either device is positioned in a huge market and we believe would shield our Company from the uncertainties of our current market.
This means that we will have to raise funds to rebuild US sales distribution channels for 2016. Hopefully, this will be facilitated by an increase in the market value of our stock. Fund-raising efforts are scheduled to start in 6 to 8 months. In the meantime, we will continue to be dependent upon the whims of the North American pQCT research market in 2015.

Regarding our stock price, I am pleased to report that we successfully worked with the OTC Markets Group to upgrade in 2014 the status of our shares in the pink sheet market to the "Current Information" top tier. As a result, trading has significantly increased and the market price of our shares has increased 100 fold from a 2013 low of $0.0014 to a 2014 high of $0.14. The bid price on December 31, 2014 was $0.03/share.

I want to thank every shareholder for continuing to be supportive of our Company.

Very truly yours,



Reynald Bonmati
Chairman of the Board and President



pQCT® XCT





WBV Galileo™/VibraFlex®



Leonardo™



SmartStep® systems



Tailwind™ system

FORWARD-LOOKING STATEMENTS

Statements made in this letter and the information incorporated by reference into this letter that are not historical factual statements are ‘‘forward-looking statements’’ within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Action of 1995 and are including this section for purposes of complying with those safe harbor provisions. The forward-looking statements include, among other things, statements regarding the intent, belief or expectations of Orthometrix, Inc. and its officers and can be identified by the use of terminology such as ‘‘may’’, ‘‘will’’, ‘‘expect’’, ‘‘believe’’, ‘‘intend’’, ‘‘plan’’, ‘‘estimate’’, ‘‘should’’ and other comparable terms or the negative thereof. In addition, we, through our senior management, from time to time make forward-looking oral and written public statements concerning our expected future operations and other developments. You are cautioned that, while forward-looking statements reflect our good faith belief and best judgment based upon current information, they are not guarantees of future performance and are subject to known and unknown risks and uncertainties. These risks and uncertainties could cause actual results to differ materially from expectations, and we disclaim any intention or obligation to update or revise any forward-looking statements or to update the reasons why actual results could differ materially from results projected in the forward-looking statement as a result of new information, future events or otherwise. Any forward-looking statements, whether made in this letter or elsewhere, should be considered in context with the risk factors discussed or incorporated by reference in this letter.